PE57898A1 - Derivados de sulfonil urea - Google Patents

Derivados de sulfonil urea

Info

Publication number
PE57898A1
PE57898A1 PE1998000051A PE00005198A PE57898A1 PE 57898 A1 PE57898 A1 PE 57898A1 PE 1998000051 A PE1998000051 A PE 1998000051A PE 00005198 A PE00005198 A PE 00005198A PE 57898 A1 PE57898 A1 PE 57898A1
Authority
PE
Peru
Prior art keywords
alkyl
rent
formula
group
zero
Prior art date
Application number
PE1998000051A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
James Frederick Eggler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE57898A1 publication Critical patent/PE57898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) o SU SAL, DONDE R1 ES (C1-C6)ALQUILO OPCIONALMENTE SUSTITUIDO POR (C1-C6)ALQUILAMINO, (C1-C6)ALQUILTIO, ENTRE OTROS; R1 Y R2 SON a)UN GRUPO DE FORMULA (II); n ES 0-3; "A, B, D, E Y G" SON O, S, N o CR5R6, R5 Y R6 SON H, (C1-C6)ALQUILO, OPCIONALMENTE SUSTITUIDO POR (C1-C6)ALQUILAMINO, (C1-C6)ALQUILTIO, ENTRE OTROS; b)UN GRUPO DE FORMULA (III), s ES CERO-6, t ES CERO-1; "X" ES O o NR8, R8 ES H, (C1-C6)ALQUILO o (C3-C7)CICLOALQUIL(C1-C6)ALQUILO; "Y" ES H, OH, (C1-C6)ALQUILO OPCIONALMENTE SUSTITUIDO POR HALO, OH, CN, ENTRE OTROS; c)UN GRUPO DE LA FORMULA (IV), u ES CERO-2, R19 ES H, (C1-C6)ALQUILO o PERFLUORO(C1-C6)ALQUILO; R20 ES H, (C1-C6)ALQUILO, (C1-C6)CARBOXIALQUILO d)UN GRUPO DE FORMULA (V), a Y e SON 0-2, b Y d SON 0-1, c ES 1-3; "J Y L" SON O o S; R21 ES H, OH, F, ENTRE OTROS; R22 ES H, (C1-C6)ALQUILO OPCIONALMENTE SUSTITUIDO POR OH, HALO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS 4-(1-HIDROXI-1-METIL-ETIL)-FURAN-2-SULFONAMIDA; 1-(4-CLORO-2,6 DIISOPROPIL-FENIL)-3-[3-(1-HIDROXI-1-METIL-ETIL)BENCENOSULFONIL]UREA; ENTRE OTROS. EL COMPUESTO I INHIBE LA TRANSFORMACION Y LIBERACION DE INTERLEUCINA-1O E INTERLEUCINA-1�. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE LA MENINGITIS, SALPINGITIS, CHOQUE SEPTICO, COAGULACION INTRAVASCULAR DISEMINADA
PE1998000051A 1997-01-29 1998-01-23 Derivados de sulfonil urea PE57898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29

Publications (1)

Publication Number Publication Date
PE57898A1 true PE57898A1 (es) 1999-06-11

Family

ID=21891776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000051A PE57898A1 (es) 1997-01-29 1998-01-23 Derivados de sulfonil urea

Country Status (40)

Country Link
US (2) US6166064A (es)
EP (1) EP0964849B1 (es)
JP (1) JP3573757B2 (es)
KR (1) KR100324058B1 (es)
CN (1) CN1127479C (es)
AP (1) AP929A (es)
AR (1) AR011093A1 (es)
AT (2) ATE242208T1 (es)
AU (1) AU723895B2 (es)
BG (1) BG103597A (es)
BR (1) BR9714328A (es)
CA (1) CA2279186C (es)
CO (1) CO4920230A1 (es)
CZ (1) CZ293173B6 (es)
DE (2) DE69729762T2 (es)
DK (2) DK0964849T3 (es)
DZ (1) DZ2407A1 (es)
EA (1) EA001803B1 (es)
ES (2) ES2222426T3 (es)
HR (1) HRP980045B1 (es)
HU (1) HUP0000567A3 (es)
ID (1) ID22223A (es)
IL (1) IL130855A0 (es)
IS (1) IS5099A (es)
MA (1) MA26468A1 (es)
NO (1) NO313279B1 (es)
NZ (1) NZ336248A (es)
OA (1) OA11079A (es)
PA (1) PA8444701A1 (es)
PE (1) PE57898A1 (es)
PL (1) PL335052A1 (es)
PT (2) PT1270565E (es)
SK (1) SK283679B6 (es)
TN (1) TNSN98017A1 (es)
TR (1) TR199901816T2 (es)
TW (1) TW515788B (es)
UY (1) UY24861A1 (es)
WO (1) WO1998032733A1 (es)
YU (1) YU33799A (es)
ZA (1) ZA98685B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
WO2001019390A1 (en) * 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US6780859B2 (en) 2001-09-14 2004-08-24 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
CA2468706A1 (en) * 2001-11-30 2003-06-05 Mark Anthony Dombroski Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
WO2004031777A1 (en) * 2002-10-03 2004-04-15 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
AR046078A1 (es) 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
WO2005090295A2 (en) * 2004-03-23 2005-09-29 Dompe' Pha.R.Ma S.P.A. 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AR052476A1 (es) 2005-02-04 2007-03-21 Senomyx Inc Compuestos que comprenden restos heteroarilo conectados y su uso como modificadores novedosos del sabor umami, estmuladores e intensificadores del gusto para composiciones comestibles
WO2006090921A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物のリンパ球活性化抑制作用
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
EP3398452A3 (en) 2006-04-21 2018-11-28 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CA2957566C (en) 2014-08-12 2023-08-01 Daniel Paul Becker Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
WO2016131098A1 (en) * 2015-02-16 2016-08-25 The University Of Queensland Sulfonylureas and related compounds and use of same
US10688077B2 (en) * 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
CA3014487A1 (en) 2016-02-16 2017-08-24 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
WO2017184604A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
EP3872070A1 (en) * 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
MY197636A (en) 2017-01-23 2023-06-29 Genentech Inc Chemical compounds as inhibitors of interleukin-1 activity
WO2018215818A1 (en) * 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
ES2906280T3 (es) 2017-07-07 2022-04-18 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
EP3658539B1 (en) 2017-07-24 2024-02-21 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
SG11202001112RA (en) 2017-08-15 2020-03-30 Inflazome Ltd Novel sulfonamide carboxamide compounds
EP3668842A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP3692020A1 (en) 2017-10-03 2020-08-12 Inflazome Limited Novel compounds
ES2927851T3 (es) * 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
GB201721185D0 (en) * 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2020010143A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Nlrp modulators
MA53170A (fr) 2018-07-20 2021-05-26 F Hoffmann La Roche Sa Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020086732A1 (en) 2018-10-24 2020-04-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
KR20210114967A (ko) 2019-01-14 2021-09-24 카딜라 핼쓰캐어 리미티드 신규 치환된 설포닐우레아 유도체
WO2020254697A1 (en) 2019-06-21 2020-12-24 Ac Immune Sa Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
JP2022548869A (ja) * 2019-09-12 2022-11-22 カディラ・ヘルスケア・リミテッド 新規な置換スルホキシミン誘導体
WO2021249337A1 (zh) * 2020-06-11 2021-12-16 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物
IL299084A (en) 2020-06-19 2023-02-01 Ac Immune Sa History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
BR112023003792A2 (pt) 2020-09-04 2023-03-28 Nodthera Ltd Derivados de sulfamoil ureia contendo porção alquil-oxacicloalquila e usos dos mesmos
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2023156311A1 (en) * 2022-02-15 2023-08-24 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) * 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
NO993658L (no) 1999-09-28
AU723895B2 (en) 2000-09-07
YU33799A (sh) 2002-03-18
EP0964849B1 (en) 2003-06-04
HRP980045A2 (en) 1999-06-30
DK0964849T3 (da) 2003-08-25
IS5099A (is) 1999-06-29
DK1270565T3 (da) 2004-10-04
IL130855A0 (en) 2001-01-28
KR100324058B1 (ko) 2002-02-16
WO1998032733A1 (en) 1998-07-30
MA26468A1 (fr) 2004-12-20
SK283679B6 (sk) 2003-11-04
CZ293173B6 (cs) 2004-02-18
NO993658D0 (no) 1999-07-28
DE69729762T2 (de) 2005-07-14
CO4920230A1 (es) 2000-05-29
AP929A (en) 2001-01-18
KR20000070541A (ko) 2000-11-25
TNSN98017A1 (fr) 2005-03-15
AU5234098A (en) 1998-08-18
PL335052A1 (en) 2000-03-27
JP3573757B2 (ja) 2004-10-06
CN1127479C (zh) 2003-11-12
ZA98685B (en) 1999-07-29
CA2279186C (en) 2004-02-24
BR9714328A (pt) 2000-03-21
ATE270285T1 (de) 2004-07-15
DE69722663T2 (de) 2004-04-29
ATE242208T1 (de) 2003-06-15
BG103597A (bg) 2000-02-29
EA199900603A1 (ru) 2000-02-28
US6433009B1 (en) 2002-08-13
TW515788B (en) 2003-01-01
TR199901816T2 (xx) 1999-11-22
AP9801190A0 (en) 1998-03-31
HUP0000567A2 (hu) 2000-10-28
CA2279186A1 (en) 1998-07-30
US6166064A (en) 2000-12-26
HUP0000567A3 (en) 2002-10-28
NZ336248A (en) 2000-10-27
AR011093A1 (es) 2000-08-02
PA8444701A1 (es) 2000-05-24
EA001803B1 (ru) 2001-08-27
PT1270565E (pt) 2004-09-30
DE69729762D1 (de) 2004-08-05
UY24861A1 (es) 2000-09-29
PT964849E (pt) 2003-08-29
CZ257599A3 (cs) 2000-09-13
OA11079A (en) 2002-03-14
JP2000511200A (ja) 2000-08-29
ID22223A (id) 1999-09-16
HRP980045B1 (en) 2002-10-31
DE69722663D1 (de) 2003-07-10
ES2222426T3 (es) 2005-02-01
CN1245490A (zh) 2000-02-23
EP0964849A1 (en) 1999-12-22
ES2198598T3 (es) 2004-02-01
SK98299A3 (en) 2001-10-08
DZ2407A1 (fr) 2003-01-04
NO313279B1 (no) 2002-09-09

Similar Documents

Publication Publication Date Title
PE57898A1 (es) Derivados de sulfonil urea
PE52799A1 (es) Cicloalquilo, lactama, lactona y compuestos relacionados, composiciones farmaceuticas que comprenden los mismos, como inhibidores de la liberacion de peptido �-amiloide y no cicloalquilo, lactama, lactona y compuestos relacionados, como inhibidores de la liberacion del peptido �-amiloide
ATE421248T1 (de) Antiseptische zusammensetzungen und verfahren
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
DE69214587T2 (de) Methanoanthracene als Dopaminantagonisten
DE69229738D1 (de) Antiseborrhoische zusammensetzung
DK0705112T3 (da) Sammensætninger til deodorisering af animalske ekskrementer og dertil hørende fremgangsmåde til deodorisering
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
MX170951B (es) Composicion antimicrobiana y metodo de uso
DE59202561D1 (de) 1,3,5-triazin-2,4,6-tris-alkylaminocarbonsäureaminoester, diese enthaltende biozide mittel sowie verfahren zu ihrer herstellung.
DE60121459D1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
ES2092645T3 (es) Metanoantracenos como antagonistas de dopamina.
ATE12335T1 (de) Anwendung von o-phenyl-hydroxylamin und bestimmte derivate davon als pflanzenwachstumsfaktoren.
AU2002100152B4 (en) Parasiticide composition
BR8702878A (pt) Composicoes,processo de tratamento de plantas para combater infeccao microbicida na planta,compostos,processo para a preparacao dos ditos compostos e composicoes e material de propagacao de plantas cultivadas
DE68903893D1 (de) 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
TH13275EX (th) สารต่อต้านการออกซิไดส์ชนิดใหม่
TH6767EX (th) อนุพันธ์ n-แอลคิลเบนซีนซัลโฟนิล คาร์โบโมอิล-5-คลอโรโซไธอะโซล และสารฆ่าจุลชีพที่ประกอบด้วยสารนั้น
TH13275A (th) สารต่อต้านการออกซิไดส์ชนิดใหม่

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed